Amgen Q2 FY26 GAAP EPS rises 65% to $4.37; revenue increases 10% to $10.1 billion

Reuters2026/08/04 20:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amgen Q2 2026 revenue rose 10% to $10.1 billion; GAAP diluted EPS jumped 65% to $4.37.
GAAP operating income climbed to $3.5 billion; operating margin widened 6.5 percentage points to 36.8%.
Free cash flow increased to $3.5 billion from $1.9 billion, reflecting the final repatriation tax payment in Q2 2025.
Repatha sales rose 37% to $953 million; Prolia sales fell 32% to $759 million as multiple biosimilars launched globally.
2026 guidance: revenue $38.2 billion-$39.4 billion; GAAP EPS $15.80-$17.08; non-GAAP EPS $22.30-$23.50.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amgen Q2 FY26 GAAP EPS rises 65% to $4.37; revenue increases 10% to $10.1 billion

You may also like

Crypto prices